Targeted Oncology interviews feature the world's leading oncologists sharing their insights on the latest news and advances in diagnostic testing, biomarkers, pathways, immunotherapy, and targeted therapeutics for better application into clinical practice.

Rationale, Data, and Future of Using Ide-Cel CAR T-Cell Therapy

September 01, 2021

Larry D. Anderson, Jr, MD, PhD, discusses the rationale behind using chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma, data from the KarMMa trial, and other trials investigating this treatment.